181 related articles for article (PubMed ID: 31029672)
1. Urologist Practice Structure and Spending for Prostate Cancer Care.
Modi PK; Herrel LA; Kaufman SR; Yan P; Borza T; Skolarus TA; Schroeck FR; Hollenbeck BK; Shahinian VB
Urology; 2019 Aug; 130():65-71. PubMed ID: 31029672
[TBL] [Abstract][Full Text] [Related]
2. Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.
Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Borza T; Schroeck FR; Jacobs BL; Skolarus TA; Shahinian VB
Eur Urol; 2018 Apr; 73(4):491-498. PubMed ID: 28823605
[TBL] [Abstract][Full Text] [Related]
3. Variation in Practice Patterns and Reimbursements Between Female and Male Urologists for Medicare Beneficiaries.
Nam CS; Mehta A; Hammett J; Kim FY; Filson CP
JAMA Netw Open; 2019 Aug; 2(8):e198956. PubMed ID: 31397864
[TBL] [Abstract][Full Text] [Related]
4. The Influence of Practice Structure on Urologists' Treatment of Men With Low-Risk Prostate Cancer.
Mitchell JM; Gresenz CR
Med Care; 2022 Sep; 60(9):665-672. PubMed ID: 35880758
[TBL] [Abstract][Full Text] [Related]
5. Urologist practice structure and quality of prostate cancer care.
Modi PK; Yan P; Hollenbeck BK; Kaufman SR; Borza T; Skolarus TA; Schroeck FR; Ryan AM; Shahinian VB; Herrel LA
Urol Pract; 2020 Sep; 7(5):419-424. PubMed ID: 34541260
[TBL] [Abstract][Full Text] [Related]
6. Practice-Level Adoption of Conservative Management for Prostate Cancer.
Modi PK; Kaufman SR; Herrel LA; Dupree JM; Luckenbaugh AN; Skolarus TA; Hollenbeck BK; Shahinian VB
J Oncol Pract; 2019 Oct; 15(10):e863-e869. PubMed ID: 31509481
[TBL] [Abstract][Full Text] [Related]
7. Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations.
Modi PK; Kaufman SR; Borza T; Yan P; Miller DC; Skolarus TA; Hollingsworth JM; Norton EC; Shahinian VB; Hollenbeck BK
Cancer; 2018 Aug; 124(16):3364-3371. PubMed ID: 29905943
[TBL] [Abstract][Full Text] [Related]
8. Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees.
Marchetti KA; Oerline M; Hollenbeck BK; Kaufman SR; Skolarus TA; Shahinian VB; Caram MEV; Modi PK
Urology; 2021 Sep; 155():77-82. PubMed ID: 33610652
[TBL] [Abstract][Full Text] [Related]
9. Physician and facility drivers of spending variation in locoregional prostate cancer.
Rodin D; Chien AT; Ellimoottil C; Nguyen PL; Kakani P; Mossanen M; Rosenthal M; Landrum MB; Sinaiko AD
Cancer; 2020 Apr; 126(8):1622-1631. PubMed ID: 31977081
[TBL] [Abstract][Full Text] [Related]
10. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF
BMC Urol; 2015 Apr; 15():25. PubMed ID: 25885745
[TBL] [Abstract][Full Text] [Related]
11. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
[TBL] [Abstract][Full Text] [Related]
12. Reimbursement and use of intensity-modulated radiation therapy for prostate cancer.
Shahinian VB; Kaufman SR; Yan P; Herrel LA; Borza T; Hollenbeck BK
Medicine (Baltimore); 2017 Jun; 96(25):e6929. PubMed ID: 28640073
[TBL] [Abstract][Full Text] [Related]
13. Urologists' use of intensity-modulated radiation therapy for prostate cancer.
Mitchell JM
N Engl J Med; 2013 Oct; 369(17):1629-37. PubMed ID: 24152262
[TBL] [Abstract][Full Text] [Related]
14. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
15. Documenting Horizontal Integration Among Urologists Who Treat Prostate Cancer.
Mitchell JM; Gresenz CR
Med Care Res Rev; 2022 Feb; 79(1):141-150. PubMed ID: 33331217
[TBL] [Abstract][Full Text] [Related]
16. Health care delivery system contributions to management of newly diagnosed prostate cancer.
Krampe N; Kaufman SR; Oerline MK; Hill D; Caram MEV; Shahinian VB; Hollenbeck BK; Maganty A
Cancer Med; 2023 Aug; 12(16):17346-17355. PubMed ID: 37475511
[TBL] [Abstract][Full Text] [Related]
17. Medicare fee reductions and the overuse of intensity-modulated radiotherapy.
Howard DH; Hockenberry J
Health Serv Res; 2021 Aug; 56(4):626-634. PubMed ID: 33905136
[TBL] [Abstract][Full Text] [Related]
18. Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.
Faraj KS; Kaufman SR; Herrel LA; Maganty A; Oerline MK; Caram MEV; Shahinian VB; Hollenbeck BK
Cancer; 2024 May; 130(9):1609-1617. PubMed ID: 38146764
[TBL] [Abstract][Full Text] [Related]
19. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
20. Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.
Agochukwu-Mmonu N; Qin Y; Kaufman S; Oerline M; Vince R; Makarov D; Caram MV; Chapman C; Ravenell J; Hollenbeck BK; Skolarus TA
JCO Oncol Pract; 2023 May; 19(5):e763-e772. PubMed ID: 36657098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
